NRP1 and carcinoma: Since EG3287 had no significant effect on the cell expression of integrin-β1 (data not shown), the inhibitory effects of the NRP1 antagonist on carcinoma cell responses, including adhesion and migration, were unlikely to have been mediated through downregulation of integrin-β1 expression.